Curative radiation therapy in prostate cancer

Area of Science:

• Oncology
• Medical Physics
• Radiation Oncology

Background:

• Radiotherapy has seen significant advancements, including multileaf collimators and computed tomography (CT)-based planning, enabling three-dimensional conformal external beam radiation therapy (3DCRT).
• Developments in brachytherapy planning systems and accelerator technology, such as image-guided radiation therapy (IGRT), have enhanced precision and allowed for reduced margins to normal tissues.
• These technological improvements permit higher radiation doses to the prostate, potentially improving treatment efficacy.

Purpose of the Study:

• To review the recent developments in radiotherapy techniques for prostate cancer.
• To compare the outcomes of radiotherapy and radical prostatectomy as curative treatment modalities.
• To assess the current evidence regarding the efficacy of these treatments for different risk groups of prostate cancer.

Main Methods:

• Review of recent technological advancements in external beam radiotherapy (3DCRT, IGRT) and brachytherapy.
• Analysis of published outcome data comparing radiotherapy and radical prostatectomy for prostate cancer.
• Evaluation of treatment effectiveness based on prostate cancer risk stratification (low-, intermediate-, and high-risk).

Main Results:

• Technological innovations like 3DCRT and IGRT have significantly improved radiation delivery precision for prostate cancer.
• Despite decades of use, no randomized trials directly compare radiotherapy and radical prostatectomy.
• Existing outcome data indicate comparable efficacy between radiotherapy and radical prostatectomy for low- and intermediate-risk prostate cancer.

Conclusions:

• Modern radiotherapy techniques offer precise dose delivery and enable higher doses to the prostate.
• Radiotherapy and radical prostatectomy are considered comparable treatment options for low- and intermediate-risk prostate cancer based on current evidence.
• Further research, including randomized trials, is needed to definitively compare these modalities across all risk groups.